

CITATION REPORT

List of articles citing

Pharmacokinetic optimisation of asthma treatment

DOI: 10.2165/00003088-199426050-00006
Clinical Pharmacokinetics, 1994, 26, 396-418.

Source: <https://exaly.com/paper-pdf/25418518/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
64	Drug interactions increase the risk and cost of theophylline toxicity. <i>Drugs and Therapy Perspectives</i> , 1994 , 4, 14-16	1.5	
63	Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma. <i>Clinical Pharmacokinetics</i> , 1995 , 29, 213-20	6.2	1
62	[Mechanisms of action of glucocorticoids. Application to the treatment of respiratory inflammation]. <i>Archivos De Bronconeumologia</i> , 1996 , 32, 527-34	0.7	1
61	Inhaled beta receptor agonists: Pharmacokinetic aspects in clinical setting. <i>Intensive Care Medicine</i> , 1996 , 22, S140-S140	14.5	
60	Aerosol deposition in equine lungs following ultrasonic nebulisation versus jet aerosol delivery system. <i>Equine Veterinary Journal</i> , 1997 , 29, 388-93	2.4	33
59	Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1997 , 22, 119-26	2.2	14
58	Aerosol therapy in the equine species. <i>Veterinary Journal</i> , 1997 , 154, 189-202	2.5	24
57	Surface-modified antiasthmatic dry powder aerosols inhaled intratracheally reduce the pharmacologically effective dose. <i>Pharmaceutical Research</i> , 1998 , 15, 1753-9	4.5	14
56	Clinical pharmacokinetics of vasodilators. Part II. <i>Clinical Pharmacokinetics</i> , 1998 , 35, 9-36	6.2	56
55	Theophylline. A review of its potential steroid sparing effects in asthma. <i>Drugs</i> , 1998 , 56, 1081-91	12.1	28
54	Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease. <i>Thorax</i> , 1999 , 54, 730-6	7.3	26
53	The influence of active secretion processes on intestinal absorption of salbutamol in the rat. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001 , 52, 31-7	5.7	17
52	Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. <i>Journal of Pharmaceutical Sciences</i> , 2001 , 90, 749-84	3.9	358
51	Clinical pharmacokinetics of salmeterol. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 19-30	6.2	76
50	Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 1077-94	6.2	121
49	Assessment of Comparative Bioequivalence of Two Metered-Dose Inhaler Formulations of Salbutamol. <i>Clinical Drug Investigation</i> , 2002 , 22, 435-441	3.2	
48	Mild dehydration: a risk factor of broncho-pulmonary disorders?. <i>European Journal of Clinical Nutrition</i> , 2003 , 57 Suppl 2, S81-7	5.2	28

47	Differential pharmacokinetics of theophylline in elderly patients. <i>Drugs and Aging</i> , 2003 , 20, 71-84	4.7	33
46	Long acting beta-agonists versus theophylline for maintenance treatment of asthma. <i>Cochrane Database of Systematic Reviews</i> , 2000 , CD001281		20
45	Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004 , 95, 120-3		6
44	Neonatal exposure to drugs in breast milk. <i>Pharmaceutical Research</i> , 2004 , 21, 555-66	4.5	30
43	Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. <i>Journal of Pharmaceutical Sciences</i> , 2004 , 93, 1641-8	3.9	31
42	[SENP-SEICAP (Spanish Society of Pediatric Pneumology. Spanish Society of Pediatric Clinical Immunology and Allergology) consensus on asthma, pneumonology, and pediatric allergy (Draft)]. <i>Allergologia Et Immunopathologia</i> , 2004 , 32, 104-18	1.9	3
41	Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. <i>Expert Opinion on Drug Delivery</i> , 2005 , 2, 519-32	8	35
40	[Consensus on the treatment of asthma in pediatrics]. <i>Anales De Pediatria</i> , 2006 , 64, 365-78	0.2	4
39	Consensus statement on the management of paediatric asthma. <i>Allergologia Et Immunopathologia</i> , 2006 , 34, 88-101	1.9	6
38	The Application of Pulmonary Inhalation Technology to Drug Discovery. <i>Annual Reports in Medicinal Chemistry</i> , 2006 , 41, 383-393	1.6	4
37	Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. <i>The Cochrane Library</i> , 2007 , CD001281	5.2	23
36	[Consensus on the treatment of asthma in pediatrics]. <i>Anales De Pediatria</i> , 2007 , 67, 253-73	0.2	10
35	The discovery of long acting beta2-adrenoceptor agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 4012-5	2.9	39
34	The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 6188-91	2.9	28
33	Recent developments of enantioseparation techniques for adrenergic drugs using liquid chromatography and capillary electrophoresis: a review. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008 , 862, 1-14	3.2	71
32	Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008 , 18, 1284-7	2.9	21
31	Consensus statement on the management of paediatric asthma. Update 2007. First Spanish Consensus for the Management of Asthma in Paediatrics. <i>Allergologia Et Immunopathologia</i> , 2008 , 36, 31-52	1.9	3
30	Development of alpha-tocopherol acetate nanoparticles: influence of preparative processes. <i>Drug Development and Industrial Pharmacy</i> , 2009 , 35, 216-23	3.6	13

29	A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010 , 20, 5302-7	2.9	22
28	Inhalation by design: novel ultra-long-acting (2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 6640-52	8.3	66
27	Inhalation by design: novel tertiary amine muscarinic M1 receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 6888-904	8.3	25
26	Nanosized rods agglomerates as a new approach for formulation of a dry powder inhaler. <i>International Journal of Nanomedicine</i> , 2011 , 6, 311-20	7.3	18
25	Direct monitoring changes of salbutamol concentration in serum by chemiluminescent imaging. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011 , 879, 2089-94	3.2	0
24	Metabolism and pharmacokinetics of indacaterol in humans. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 1712-22	4	16
23	Tremor and (2)-adrenergic agents: is it a real clinical problem?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012 , 25, 4-10	3.5	22
22	Deposition of Inhaled Particles in the Lungs. <i>Archivos De Bronconeumologia</i> , 2012 , 48, 240-246	0.7	86
21	Deposition of inhaled particles in the lungs. <i>Archivos De Bronconeumologia</i> , 2012 , 48, 240-6	0.7	58
20	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 379-89	4	47
19	Circadian events in human diseases and in cytochrome P450-related drug metabolism and therapy. <i>IUBMB Life</i> , 2013 , 65, 487-96	4.7	25
18	Pulmonary Pharmacology. 2013 , 458-471		
17	Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 813-22	5.5	5
16	Corticosteroid and long-acting (agonist) therapy reduces epithelial goblet cell metaplasia. <i>Clinical and Experimental Allergy</i> , 2017 , 47, 1534-1545	4.1	9
15	CFD simulation of aerosol delivery to a human lung via surface acoustic wave nebulization. <i>Biomechanics and Modeling in Mechanobiology</i> , 2017 , 16, 2035-2050	3.8	40
14	Assessing the viability of long-acting (agonists) in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 129-136	5.5	4
13	Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 1122-1135	4	36
12	Pulmonary Pharmacology. 2019 , 613-628		

11	CFPD simulation of magnetic drug delivery to a human lung using an SAW nebulizer. <i>Biomechanics and Modeling in Mechanobiology</i> , 2019 , 18, 547-562	3.8	7
10	Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach. <i>Drug Metabolism and Disposition</i> , 2020 , 48, 570-579	4	2
9	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. <i>Expert Opinion on Drug Delivery</i> , 2021 , 18, 891-906	8	4
8	Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion. <i>International Journal of COPD</i> , 2021 , 16, 1021-1033	3	3
7	Salbutamol Transport and Deposition in the Upper and Lower Airway with Different Devices in Cats: A Computational Fluid Dynamics Approach. <i>Animals</i> , 2021 , 11,	3.1	1
6	Aerosol Drug Delivery. 1		1
5	Medical and pharmaceutical aerosols. 2004 , 260-284		1
4	Clinical significance of therapeutic drug monitoring in pharmacotherapy rationalization and individualization. <i>Kontakt</i> , 2005 , 7, 211-218	0.3	
3	Traitement de l'asthme (à l'exception de la désensibilisation). 2008 , 565-594		
2	Medical and Pharmaceutical Aerosols. 2012 , 1-30		
1	Deposition and Clinical Impact of Inhaled Particles in the Lung. 2023 ,		0